We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+39.96%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.48B
AUM Growth
+$386M
(+35%)
Cap. Flow
+$89.6M
Cap. Flow
% of AUM
6.06%
Top 10 Holdings %
Top 10 Hldgs %
43.47%
Holding
92
New
20
Increased
28
Reduced
19
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alignment Healthcare
ALHC
|
+$17.8M |
| 2 |
Cytokinetics
CYTK
|
+$16.5M |
| 3 |
Vera Therapeutics
VERA
|
+$12.7M |
| 4 |
Centene
CNC
|
+$12.1M |
| 5 |
Intuitive Surgical
ISRG
|
+$12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$26M |
| 2 |
Boston Scientific
BSX
|
+$25.9M |
| 3 |
DexCom
DXCM
|
+$17.5M |
| 4 |
GE HealthCare
GEHC
|
+$14.8M |
| 5 |
Encompass Health
EHC
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Tenax Therapeutics
TENX
$60.6M
| $1.27M | 0.09% |
167,000
| – | – |
|
77
AbbVie
ABBV
$442B
| – | – |
-40,000
| Closed | -$7.42M |
|
78
Alkermes
ALKS
$8.26B
| – | – |
-100,000
| Closed | -$2.86M |
|
79
Baxter International
BAX
$14.3B
| – | – |
-250,000
| Closed | -$7.57M |
|
|
CPRX
80
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-150,000
| Closed | -$3.25M |
|
81
CRISPR Therapeutics
CRSP
$5.23B
| – | – |
-100,000
| Closed | -$4.86M |
|
|
82
DexCom
DXCM
$33.8B
| – | – |
-200,000
| Closed | -$17.5M |
|
|
ETNB
83
DELISTED
89bio
ETNB
| – | – |
-1,050,000
| Closed | -$10.3M |
|
|
84
GE HealthCare
GEHC
$32.9B
| – | – |
-200,000
| Closed | -$14.8M |
|
85
Jasper Therapeutics
JSPR
$29.7M
| – | – |
-590,000
| Closed | -$3.27M |
|
86
MoonLake Immunotherapeutics
MLTX
$1.41B
| – | – |
-200,000
| Closed | -$9.44M |
|
87
Ultragenyx Pharmaceutical
RARE
$2.66B
| – | – |
-100,000
| Closed | -$3.64M |
|
88
Arcus Biosciences
RCUS
$3.66B
| – | – |
-300,000
| Closed | -$2.44M |
|
89
CALL
Viking Therapeutics
VKTX
$3.94B
| – | – |
-200,000
| Closed | -$5.3M |
|
|
VRNA
90
DELISTED
Verona Pharma
VRNA
| – | – |
-60,000
| Closed | -$5.67M |
|
91
Waters Corp
WAT
$40.7B
| – | – |
-15,000
| Closed | -$5.24M |
|
|
ATYR
92
aTyr Pharma
ATYR
$52.4M
| – | – |
-1,050,000
| Closed | -$5.32M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q3 2025 Portfolio in Review
As of Q3 2025, Integral Health Asset Management held 92 positions worth $1.48B, up 35% from $1.09B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Integral Health Asset Management deployed $89.6M of net new capital in Q3 2025, opening 20 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 400,000 shares worth $14.3M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier.
On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $26M trimmed.
- Integral Health Asset Management's largest Q3 2025 buy was Centene: 400,000 shares worth $14.3M.
- Integral Health Asset Management added most to Alignment Healthcare in Q3 2025, an estimated $17.8M increase.
- Integral Health Asset Management's biggest Q3 2025 reduction was Mineralys Therapeutics, cutting an estimated $26M.
- Integral Health Asset Management fully exited DexCom in Q3 2025, selling an estimated $17.5M.
- Integral Health Asset Management's ten largest holdings make up 43% of its $1.48B portfolio in Q3 2025.
- Integral Health Asset Management opened 20 new positions and closed 16 in Q3 2025.
- Integral Health Asset Management's portfolio value rose 35% quarter-over-quarter to $1.48B.
Based on Integral Health Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.